|
End-of-day quote
Taiwan S.E.
30/10/2026
|
5-day change | 1st Jan Change | ||
| 17.20 TWD | -1.71% |
|
-3.37% | -9.23% |
Company Valuation: Adimmune Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 19,178 | 15,184 | 13,973 | 8,472 | 7,988 | 7,250 | - |
| Change | - | -20.83% | -7.97% | -39.37% | -5.72% | -9.23% | - |
| Enterprise Value (EV) | 19,178 | 14,386 | 13,973 | 8,472 | 7,988 | 7,250 | 7,250 |
| Change | - | -24.99% | -2.87% | -39.37% | -5.72% | -9.23% | 0% |
| P/E | - | 52.4x | -21.8x | - | -33.2x | - | - |
| PBR | 3.12x | 2.45x | - | - | - | 1.43x | - |
| PEG | - | - | 0x | - | - | - | - |
| Capitalization / Revenue | 11.7x | 6.74x | - | 5.44x | - | 4.79x | 4.32x |
| EV / Revenue | 0x | 0x | - | 0x | - | 4.79x | 4.32x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | 0x | - | -0x | - | -58.5x | 558x |
| EV / FCF | - | -0x | - | - | - | -59.9x | -88.4x |
| FCF Yield | - | -4.69% | - | - | - | -1.67% | -1.13% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | - | 0.68 | -1.52 | - | -0.57 | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1,641 | 2,252 | - | 1,557 | - | 1,515 | 1,677 |
| EBITDA | - | 352.9 | - | -119.3 | - | - | - |
| EBIT 1 | -206.8 | 93.57 | - | -298.9 | - | -124 | 13 |
| Net income | - | 291 | -639.9 | - | -239.9 | - | - |
| Net Debt | - | -797.9 | - | - | - | - | - |
| Reference price 2 | 44.65 | 35.60 | 33.15 | 20.10 | 18.95 | 17.20 | 17.20 |
| Nbr of stocks (in thousands) | 429,508 | 426,508 | 421,508 | 421,508 | 421,508 | 421,508 | - |
| Announcement Date | 30/03/22 | 30/03/23 | 28/03/24 | 31/03/25 | 31/03/26 | - | - |
1TWD in Million2TWD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 222M | |
| 41.54x | 14.06x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 38.61x | 8.62x | 17.83x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 109.15x | 6.06x | 25.73x | 2.28% | 369B | |
| 23.19x | 5.97x | 14.41x | 2.71% | 307B | |
| 24.47x | 4.9x | 13.63x | 1.77% | 290B | |
| 29.56x | 7.53x | 13.48x | 2.16% | 252B | |
| -49.1x | 7.47x | 29.35x | 1.93% | 212B | |
| Average | 31.02x | 7.40x | 19.73x | 2.01% | 426.22B | |
| Weighted average by Cap. | 37.29x | 8.84x | 21.96x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 4142 Stock
- Valuation Adimmune Corporation
Select your edition
All financial news and data tailored to specific country editions
